{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:11:25Z","timestamp":1696399885440},"reference-count":52,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T00:00:00Z","timestamp":1386633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction and Aims<\/jats:title><jats:p>Previous studies have suggested that methadone is associated with prolonged corrected\u2010QT (<jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content>) interval, but published prospective research studies in this area are relatively scarce. This study investigates <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval change among methadone maintenance patients and possible associated risk factors. One of the aims is to explore the effect of amphetamines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and Methods<\/jats:title><jats:p>This prospective cohort study with six\u2010month follow up assesses the effect of methadone on <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval among a sample (<jats:italic>n<\/jats:italic>\u2009<jats:italic>=<\/jats:italic>\u2009170) of heroin users in a methadone maintenance treatment program in <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>aiwan. Demographic data, substance use history, medical history and laboratory studies were collected at study enrollment. Twelve\u2010lead electrocardiograms were performed for all participants both at study enrollment and six months later.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median daily methadone dose was 41\u2009mg. A mean increase of <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval (17.1\u2009ms, <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>\u2009<jats:italic>=<\/jats:italic>\u200950.0, <jats:italic>P<\/jats:italic>\u2009<jats:italic>&lt;<\/jats:italic>\u20090.001) was found at six\u2010month follow up. <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval prolongation in the sample at baseline was 2.9%, and at six months was 12.4%. A positive correlation was found between comorbid amphetamine use frequency in the past month and <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval change. Methadone dose was not associated with <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> change.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>An increase of mean <jats:styled-content style=\"fixed-case\">QTc<\/jats:styled-content> interval was found among methadone maintenance patients at six\u2010month follow up. Electrocardiogram monitoring should be performed among patients who are at risk of frequently using amphetamines during methadone maintenance treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.12099","type":"journal-article","created":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T08:20:54Z","timestamp":1386663654000},"page":"194-201","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of amphetamine on corrected\u2010QT interval change during methadone maintenance treatment in <scp>T<\/scp>aiwan: A prospective cohort study"],"prefix":"10.1111","volume":"33","author":[{"given":"Ni\u2010Chi","family":"Lin","sequence":"first","affiliation":[{"name":"Tsaotun Psychiatric Centre Ministry of Health and Welfare  Nan\u2010Tou Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh\u2010Liang","family":"Huang","sequence":"additional","affiliation":[{"name":"College of Medicine China Medical University  Taichung Taiwan"},{"name":"Centre for Drug Abuse &amp; Addiction China Medical University Hospital  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung\u2010Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Tsaotun Psychiatric Centre Ministry of Health and Welfare  Nan\u2010Tou Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsang\u2010Yaw","family":"Lin","sequence":"additional","affiliation":[{"name":"Tsaotun Psychiatric Centre Ministry of Health and Welfare  Nan\u2010Tou Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu\u2010Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Tsaotun Psychiatric Centre Ministry of Health and Welfare  Nan\u2010Tou Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye\u2010Hsu","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Internal Medicine Kaohsiung Medical University Chung\u2010Ho Memorial Hospital  Kaohsiung City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin\u2010Mei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Taichung Veterans General Hospital  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent Chin\u2010Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Chung Shan Medical University  Taichung Taiwan"},{"name":"Department of Psychiatry Chung Shan Medical University Hospital  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gossop","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-6-200209170-00010"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1112"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(02)00461-X"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.100180"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.06.018"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000081416"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03767.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.22.2469"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.11.055"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2011.02231.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8651(05)70143-0"},{"key":"e_1_2_6_13_1","unstructured":"European Medicines Agency (EMA).ICH Topic E 14: the Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non\u2010antiarrhythmic Drugs 2005. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002879.pdf(accessed September 2012)."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.038240"},{"key":"e_1_2_6_15_1","first-page":"210","article-title":"Methadone\u2010induced mortality in the treatment of chronic pain: role of QT prolongation","volume":"16","author":"Andrews CM","year":"2009","journal-title":"Cardiol J"},{"key":"e_1_2_6_16_1","unstructured":"European Medicines Agency (EMA).EMEA Public Statement on the Recommendation to Suspend the Marketing Authorisation for ORLAAM (Levacetylmethadol) in the European Union 2001. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/12\/WC500018335.pdf(accessed May 2012)."},{"key":"e_1_2_6_17_1","unstructured":"US Food and Drug Administration (FDA).Information for Healthcare Professionals Methadone Hydrochloride Text Version: Death Narcotic Overdose and Serious Cardiac Arrhythmias. [FDA Alert] 2006. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm142841.htm(accessed November 2013)."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.12.1280"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.01.040"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.11.1363"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000085057.63483.9b"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.9656771.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.02.007"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-9-18"},{"key":"e_1_2_6_25_1","unstructured":"United Nations Office on Drugs and Crime (UNODC).World Drug Report 2012 (United Nations Publication Sales No. E.12.XI.1) 2012. Available at:http:\/\/www.unodc.org\/documents\/data\u2010and\u2010analysis\/WDR2012\/WDR_2012_web_small.pdf(accessed September 2012)."},{"key":"e_1_2_6_26_1","first-page":"180","article-title":"QT\u2010interval prolongation with Ecstasy","volume":"86","author":"Drake WM","year":"1996","journal-title":"S Afr Med J"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2001.tb143372.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00237.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60291-8"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-7-292"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2006.01481.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2007.01618.x"},{"issue":"20","key":"e_1_2_6_33_1","first-page":"22","article-title":"The Mini\u2010International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286900"},{"key":"e_1_2_6_35_1","unstructured":"European Medicines Agency (EMA) Committee for Proprietary Medicinal Products. Points to Consider: the Assessment of the Potential for QT Interval Prolongation by Non\u2010cardiovascular Medicinal Products. London: EMA 1997. Available at:http:\/\/www.ganimed.biz\/bibliothek\/media\/EMEA_CPMP_Dec1997.pdf(accessed November 2013)."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550880802324317"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241140-00003"},{"key":"e_1_2_6_38_1","first-page":"235","article-title":"MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?","volume":"3","author":"Torre R","year":"2012","journal-title":"Front Genet"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.05.002"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01776.x"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hdx.0000080713.09303.a6"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.paf.0000188082.68009.10"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612043152311"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.6.1799"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2011.03.042"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02549.x"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01668.x"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.103"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.96"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.42.1133"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genm.2008.05.005"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-6-200903170-00103"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-3-200908040-00014"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdar.12099","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.12099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:32:38Z","timestamp":1696321958000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.12099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,10]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/dar.12099"],"URL":"https:\/\/doi.org\/10.1111\/dar.12099","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,10]]},"assertion":[{"value":"2013-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}